EG-COVID-003
/ Eyegene
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 07, 2025
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1/2 | N=67 | Completed | Sponsor: EyeGene Inc. | Active, not recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Feb 2025
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease
February 19, 2024
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1/2 | N=67 | Active, not recruiting | Sponsor: EyeGene Inc. | Trial completion date: Apr 2024 ➔ Aug 2024 | Trial primary completion date: Dec 2023 ➔ Aug 2024
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
1 to 2
Of
2
Go to page
1